Medclair - Public Comps and Valuation Multiples

Medclair Overview

About Medclair

Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes up to 99% of the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.

Founded

2013

HQ

Employees

Website

medclair.com

Sectors

Medical Devices
HealthTech

Financials

Last FY Revenue $4.1M

Last FY EBITDA $0.3M

EV

$16.2M

Valuation Multiples

Multiples.vc

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Medclair Financials

In the most recent fiscal year, Medclair achieved revenue of $4.1M and an EBITDA of $0.3M.

Medclair expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Medclair valuation multiples based on analyst estimates

Medclair P&L

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$4.1M	XXX	XXX	XXX
Gross Profit	XXX	$2.6M	XXX	XXX	XXX
Gross Margin	XXX	62%	XXX	XXX	XXX
EBITDA	XXX	$0.3M	XXX	XXX	XXX
EBITDA Margin	XXX	8%	XXX	XXX	XXX
EBIT	XXX	-$0.3M	XXX	XXX	XXX
EBIT Margin	XXX	-7%	XXX	XXX	XXX
Net Profit	XXX	-$0.3M	XXX	XXX	XXX
Net Margin	XXX	-7%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Medclair Stock Performance

As of May 30, 2025, Medclair's stock price is SEK 2 (or $0).

Medclair has current market cap of SEK 159M (or $16.4M), and EV of SEK 157M (or $16.2M).

See Medclair trading valuation data

Medclair Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$16.2M	$16.4M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Medclair Valuation Multiples

As of May 30, 2025, Medclair has market cap of $16.4M and EV of $16.2M.

Medclair's trades at 3.9x EV/Revenue multiple, and 50.2x EV/EBITDA.

Equity research analysts estimate Medclair's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Medclair's P/E ratio is not available.

See valuation multiples for Medclair and 12K+ public comps

Medclair Financial Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$16.4M	XXX	$16.4M	XXX	XXX	XXX
EV (current)	$16.2M	XXX	$16.2M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	3.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	50.2x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-60.0x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	-57.0x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-812.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Medclair Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Medclair Margins & Growth Rates

Medclair's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

Medclair's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medclair's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Medclair and other 12K+ public comps

Medclair Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	8%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	69%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial